30 August 2024

Botanix Pharmaceuticals Releases Appendix 4E Preliminary Annual Report and Announces Commercial Day Webinar

Philadelphia PA and Phoenix AZ 30 August 2024: Clinical dermatology company, Botanix Pharmaceuticals Ltd (ASX: BOT, "**Botanix**" or "the **Company**"), is pleased to release its Appendix 4E Preliminary Annual Report for the year ended 30 June 2024.

Botanix will host a webinar on Tuesday 17 September 10:30am AEST (Sydney/Melbourne) / 8:30am AWST (Perth) to provide a comprehensive update on its commercial launch plans and market insights for *Sofdra*™.

Executive Chairman, Vince Ippolito and Chief Executive Officer, Dr Howie McKibbon, will host the call attended by key members of the Botanix commercial team, and includes valued guests George Jones, Chief Operations Officer of telehealth provider UpScript Health, Bill Bush, Managing Partner of SendRx, Jay Manara, SVP, Strategy & Planning for advertising agency Klick Health.

Mark your calendar for the Botanix Commercial Day Webinar and watch for registration details in an upcoming communication.

Release authorised by

Vince Ippolito
Executive Chairman

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US) which has received FDA approval for its lead product *Sofdra*™ for the treatment of primary axillary hyperhidrosis. *Sofdra* is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition

To learn more please visit: http://www.botanixpharma.com/

For more information, please contact:

General enquiries
Corporate Communications
Botanix Pharmaceuticals
P: +61 8 6555 2945
investors@botanixpharma.com

Investor enquiries
Hannah Howlett
WE Communications
P: +61 450 648 064
hhowlett@we-worldwide.com

Media enquiries
Haley Chartres
H^CK
P: +61 423 139 163
haley@hck.digital

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs, the Company's ability to obtain marketing approvals for is product candidates, the expected timing and/or results of regulatory approvals and the outcome and effects of *Sofdra*™ and the market for *Sofdra*. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

botanix
PHARMACEUTICALS

ACN: 009 109 755

Appendix 4E
PRELIMINARY ANNUAL REPORT

for the year ended 30 June 2024
Comparative year: 30 June 2023

Botanix Pharmaceuticals Limited

ABN: 26 636 569 634

Appendix 4E – Preliminary Final Report (unaudited)

Results for announcement to the market
For the year ended 30 June 2024
Comparative year: 30 June 2023

Key Information	2024 $	2023 $	Change $	Up / down	%
Revenues from customer sales	**601,820**	102,934	498,886	Up	484.7%
Loss from ordinary activities after tax attributable to members	**(13,869,709)**	(9,153,974)	(4,715,735)	Up	51.5%
Net loss for the period attributable to members	**(13,709,868)**	(8,917,281)	(4,792,587)	Up	53.7%

Dividends (distributions)	Amount per security	Franked amount per security
Interim dividend	Nil	- ¢
Final dividend	Nil	- ¢
Previous corresponding period	Nil	- ¢

Record date for determining entitlements to the dividend N/A

Net Tangible Assets per share	30 June 2024	30 June 2023
Net tangible asset per ordinary security (cents per share)	4.38	0.93

Brief explanation

Revenues include net royalties received from the Japanese licensee of the Sofpironium Bromide product. Botanix increased its operating costs during the year by $3,022,613 and decreased its R&D tax incentive refund by $2,201,772 resulting in an increased loss from ordinary activities of $4,715,735. The increased costs during the period were a result of increased activity to advance its *Sofdra* product through the regulatory approval processes which it achieved on 18 June 2024.

Further review of operations is included in the Directors' Report.

Status of audit

The accounts are in the process of being audited.

BOTANIX PHARMACEUTICALS LIMITED
ACN: 009 109 755

CORPORATE INFORMATION

Directors
Mr Vincent Ippolito
Executive Chairman

Mr Matthew Callahan
Executive Director

Dr William Bosch
Non-executive Director

Dr Stewart Washer
Non-executive Director

Mr Danny Sharp
Non-executive Director

Company Secretary
Ms Susan Park

Chief Financial Officer
Mr Graeme Morissey

Home Securities Exchange:
Australian Securities Exchange Limited
Level 40, Central Park
152 – 158 St George's Terrace
PERTH WA 6000

ASX Code: BOT

Share Registry
Automic Registry Services
Level 2
267 St Georges Terrace,
PERTH WA 6000
Telephone: (08) 9324 2099

Registered Office
Suite 3
41 – 47 Colin Street
West Perth Western Australia 6005
Australia
Telephone: (08) 6555 2945
Facsimile: (08) 6210 1153

Email: info@botanixpharma.com
Website: www.botanixpharma.com

Solicitors
Gilbert + Tobin
Level 16, Brookfield Place
Tower 2
123 St Georges Terrace
PERTH WA 6000

Auditor
BDO Audit Pty Ltd
Level 9
Mia Yellagonga Tower 2
5 Spring Street
PERTH WA 6000

Bankers
NAB
100 St Georges Terrace
PERTH WA 6000

DIRECTORS' REPORT

Your Directors have pleasure in submitting their report together with the financial statements of the Group consisting of Botanix Pharmaceuticals Limited and the entities it controlled during the period for the financial year ended 30 June 2024, in order to comply with the provisions of the Corporations Act 2001, the Directors report as follows:

Mr Vincent Ippolito	Executive Chairman
Mr Matthew Callahan	Executive Director
Dr William Bosch	Non-executive Director
Dr Stewart Washer	Non-executive Director
Mr Danny Sharp	Non-executive Director

PRINCIPAL ACTIVITIES

Botanix Pharmaceuticals Limited (ASX: BOT) is a dermatology company based in Philadelphia and Phoenix (US) which recently secured FDA approval for its lead product *Sofdra*™ (sofpironium) topical gel, 12.45%, a prescription anticholinergic medicine used on the skin (topical), to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children 9 years of age and older.

Sofdra is the first and only new chemical entity approved by the FDA to treat primary axillary hyperhidrosis ("hyperhidrosis") and presents a novel safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.

Hyperhidrosis is a condition characterised by abnormally increased sweating, beyond that required to regulate body temperature.[1] The disproportionate sweat production that characterises hyperhidrosis, results in a disabling medical condition with profound effects on the patient's quality of life. Hyperhidrosis affects work productivity, daily routine activities, emotional well-being and personal relationships.[2] Hyperhidrosis is the third largest dermatology condition (after acne and atopic dermatitis), with approximately 10 million patients in the US who have primary axillary hyperhidrosis.[3]

Botanix is currently preparing to launch *Sofdra* in the United States. An early patient experience program will roll out in late Q3 CY2024 to engage highly qualified patients with hyperhidrosis and allow them to gain early access to *Sofdra*. These patients will be guided through the telemedicine and payer reimbursement process to be the first commercial users of the product. Broader launch of *Sofdra* is expected to follow in Q4 CY2024.

[1] Oshima Y, Tamada Y. Classification of systemic and localized sweating disorders. In: Yokozeki H, Murota H, Katayama I, editors. Perspiration research. Current problems in dermatology, vol 51. Basel: Karger; 2016. p. 7–10
[2] Hamm H, Naumann MK, Kowalski JW, Kutt S, Kozma C, Teale C. Primary focal hyperhidrosis: disease characteristics and functional impairment. Dermatology. 2006;212(4):343–353. doi: 10.1159/000092285
[3] Dolittle, et al, 2016, Hyperhidrosis: an update on prevalence and severity in the United States, Archives of Dermatology Research

RESULTS AND FINANCIAL POSITION

The financial report has been prepared on the going concern basis, which contemplates the continuity of normal business activity, the realisation of assets and the settlement of liabilities in the normal course of business.

The Group has generated a comprehensive loss after tax for the year ended 30 June 2024 of $13,709,868 (30 June 2023: $8,917,281). The net loss is attributable primarily to the expenditure in relation to advancing regulatory approval activities and costs for *Sofdra* (sofpironium) topical gel, 12.45%. The Group had a net working capital surplus of $79,169,230 at 30 June 2024 (30 June 2023: $12,093,632) and experienced net cash outflows from operating activities for the year of $8,127,282 (30 June 2023: $12,074,064).

At 30 June 2024, the Group had a cash balance of $79,308,130 (30 June 2023: $10,250,395). The Directors believe that there are sufficient funds to meet the Group's working capital requirements. The Directors consider the going concern basis of preparation to be appropriate based on forecast cash flows and have confidence in the Company's ability to raise additional funds if required.

DIVIDENDS

There were no dividends paid or declared during the year (30 June 2023: Nil).

OPERATING AND FINANCIAL REVIEW AND FUTURE PROSPECTS

OPERATIONAL REVIEW

Overview

During the 12-month period, Botanix made significant progress with its lead asset *Sofdra* (sofpironium) topical gel, 12.45% which was approved by the FDA in late June 2024 is a prescription anticholinergic medicine used on the skin (topical), to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children 9 years of age and older.

***Sofdra*™ (sofpironium) topical gel, 12.45%**

Botanix's lead asset is *Sofdra*, a topically applied gel for the treatment of primary axillary hyperhidrosis (a medical condition that causes excessive underarm sweating), which affects 10 million individuals in the US alone. Phase 3 clinical studies were completed successfully, and primary and secondary efficacy endpoints achieved with a high degree of statistical significance, which paved the way for FDA approval granted on 18 June 2024.

Sofdra regulates sweating at the site of application, by binding to the primary sweat receptor and thereby blocking the sweat signal. The gel is delivered to the underarms using a patented applicator, which is similar to the 'roll on' commonly used in antiperspirants, which allows the patient to avoid direct drug contact with their hands. The drug is designed to be rapidly metabolized by the body as it passes through into the blood stream, (rather than traveling around the body and affecting other organs), and this is associated with reduced incidence, severity, and duration of side effects of the drug.

Two pivotal Phase 3 'CARDIGAN' studies evaluated the efficacy and safety of *Sofdra* versus vehicle in patients with primary axillary hyperhidrosis. In the studies, treatment with *Sofdra* successfully met all primary and secondary endpoints with clinically and statistically meaningful changes from baseline to day 43 in Gravimetric Sweat Production (GSP) and the Hyperhidrosis Disease Severity Measure-Axillary, 7-item (HDSM-Ax-7) score, a patient-reported sweat severity scale.

More than 700 patients were enrolled in the two Phase 3 studies and approximately 300 patients participated in a separate 48-week safety study of *Sofdra*. The majority of adverse events were mild to moderate and transient in nature. Based on these studies, the Company believes that *Sofdra* has the potential to be the best-in-class treatment for axillary hyperhidrosis, as existing therapies are less than ideal, either because of the lack of efficacy, an unfavourable side effect profile, systemic drug exposure, or produce pain from invasive injection procedures or severing of the nerves through surgery.

REVIEW OF OPERATIONS AND RESULTS

In the US, there are approximately 10 million subjects who suffer from primary axillary hyperhidrosis, which is the patient population in which the successful Phase 3 studies were conducted. Of those subjects, approximately 3.7 million subjects are actively seeking treatment. Even assuming a modest penetration of this population at the current price of competitive treatments (i.e., approximately US$7,200 per year), this provides a significant market opportunity for *Sofdra*.

The FDA approved *Sofdra*™ (sofpironium) topical gel, 12.45% on 18 June 2024.

In July 2023, Botanix paid US$8,250,000 to Fresh Tracks Therapeutics Inc (previously known as Brickell Biotech) to extinguish the contracted future milestone and royalty payments due to

Fresh Tracks under the Asset Purchase Agreement. The Company will retain an obligation to the head licensor, Bodor Laboratories, to pay a 5% royalty on net sales made by Botanix.

The Company continues to ramp up commercial launch preparation activities for *Sofdra* and is engaged with US payers (insurers) around contracting and pricing for the product, testing telemedicine and supply chain elements, finalising sales strategies, as well as preparing patient and physician-focused launch marketing and sales materials. Go-to-market media planning is also underway, focusing on developing an optimal digital media channel mix to refine, reach and motivate target audiences. Advertising creative and message exploration is advancing and the resulting campaign concepts will be validated and refined through physician and consumer research prior to launch. A CY2025 conference plan has also been developed to engage with key healthcare provider audiences.

Having successfully launched more than 30 dermatology products between them, Botanix's management team and Board have an unrivalled track record in commercializing products and exiting dermatology companies to larger partners.

Corporate

Three capital raisings were completed by Botanix during the financial year, totalling A$96,000,000. The first of these placements totalled A$12,500,000 gross proceeds from new and existing institutional and sophisticated investors. Proceeds of US$8,250,000 from this placement was used to extinguish future milestone and royalty payments due to the Company's partner Fresh Tracks—a move that could save up to $160,000,000 and prime the Company for potential M&A or partnership activity.

In December, Botanix finalised the placement of A$13,500,000 gross in new shares and then followed that with a $A70,000,000 gross raise in late June 2024, which was led by Botanix's existing institutional shareholders and included a significant number of new institutional investors. Proceeds from these placements are being applied towards preparation for commercial launch activities of *Sofdra* in the United States, as well as general working capital purposes and costs.

Complimenting these fundraises, and as a direct result of increases to the Company's share price throughout the period, the Group raised $4,854,969 from the exercise of options. Specifically, 48,664,095 of options were exercised at $0.09 and 6,000,000 of options were exercised at $0.0792.

As a result of its placements and the exercise of options as described above, the Company is well funded to bring *Sofdra* to market, including progressing with manufacturing, sales and marketing costs relevant to ramping up activity to achieve steady state sales of the product.

***Sofdra* Important Safety Information & Indication**

Indication

Sofdra (sofpironium) topical gel, 12.45% is a prescription anticholinergic medicine used on the skin (topical) to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children 9 years of age and older.

IMPORTANT SAFETY INFORMATION

***Sofdra* is for use on the skin in the underarm area only. Wash your hands right away after you apply *Sofdra*. Do not touch your underarms after applying *Sofdra*. *Sofdra* is flammable. Avoid heat and flame while applying *Sofdra*.**

Who should not use *Sofdra*?

Do not use *Sofdra* if you have certain medical conditions that can be made worse by taking an anticholinergic medicine such as glaucoma, severe ulcerative colitis (UC) or certain other serious bowel problems associated with severe UC, myasthenia gravis, and Sjogren's syndrome.

What should I tell my healthcare provider before using *Sofdra*?

- **Tell your healthcare provider about all of your medical conditions,** including bladder or kidney problems, problems passing urine, if you are pregnant or breastfeeding, or plan to become pregnant or breastfeed. It is not known if *Sofdra* will harm your unborn baby or pass into your breast milk.
- **Tell your healthcare provider about all the medicines you take,** including prescription and over-the-counter medicines, especially any anticholinergic medicines.

What are possible side effects of *Sofdra*?

Serious side effects may include:

- **Blurred vision.** Stop using *Sofdra*, call your healthcare provider right away, and do not drive or operate machinery or do hazardous work until your vision is clear.
- **New or worsened urinary retention.** Stop using *Sofdra* and call your healthcare provider right away if you experience difficulty urinating, urinating frequently, urination in a weak stream or drips, full bladder or difficulty emptying your bladder.

The most common side effects of *Sofdra* include dry mouth; blurred vision; pain, redness, swelling, itching, and irritation in the underarm area; dilation of the pupils of your eyes (mydriasis); and problems with urination. These are not all of the possible side effects of *Sofdra*. Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Botanix at 1-866-763-6337.

Keep *Sofdra* and all medicines out of the reach of children.

SIGNIFICANT CHANGES IN THE STATE OF AFFAIRS

Other than as mentioned in the Review of Operations, no significant changes in the state of affairs of the Consolidated Entity occurred during the financial year.

OPERATIONAL RISKS

There are material risks, inherent in the pharmaceutical industry that, either individually or in combination, may materially and adversely affect the future operating and financial performance and prospects of Botanix and the value of its shares. Some of these risks may be mitigated by Botanix's internal controls and processes but some are outside the control of Botanix, its directors and management. The material risks identified by management are described below:

Regulatory risks

The research, development, manufacture, marketing and sale of products developed by the Company are subject to extensive regulation by multiple government authorities and institutional bodies in the USA and other jurisdictions. Drug products must undergo a comprehensive and highly regulated development, trial and review process before receiving approval for marketing. The process includes a requirement for approval to conduct clinical trials, and the provision of data relating to the quality, safety and efficacy of the products for their proposed use. There is no guarantee that regulatory approvals to conduct clinical trials and/or to manufacture and market the Company's products will be granted.

If a product is approved, it may also be submitted for cost reimbursement approval to relevant agencies. The availability and timing of that reimbursement approval may have an impact upon the uptake and profitability of products in some jurisdictions. If the Company is unable to secure necessary approvals from regulatory agencies and institutional bodies to undertake its planned trials, market its products and obtain cost reimbursements for its products its future prospects and profitability is likely to be materially and adversely affected.

Mitigation measures employed by the Company include: engagement of suitably qualified and experienced persons with expertise in the regulation of drug products; regular review of evolving regulatory requirements and analysis of the Company's activities and plans against regulatory expectations in key jurisdictions; and ensuring that the expectations and uncertainties related to regulatory approvals, and the timing of such approvals, are included in business plans.

Manufacturing risk

The Company's development stage and planned commercial products are manufactured by contract manufacturing organisations engaged by Botanix for that purpose. The Company relies on supply relationships with third party organisations and partners for raw materials, packaging components and other consumables. An inability of these third party organisations to continue to supply the Company in a timely, economical and/or consistent manner could adversely impact on the progress of the Company's development programs and potentially on the financial performance of the Company.

Mitigation measures employed by the Company include: performing rigorous due diligence on suppliers; engaging suppliers with strong track records and sufficient capability to meet the Company's foreseeable needs; and employing a senior manager responsible for managing and monitoring the performance of third parties including suppliers.

Market Risks

The Company is subject to a number of financial risks which arise as a result of its activities. Market risk comprises three types of risk: currency risk, interest rate risk and other price risk.

Currency risk- During the normal course of business the Company enters into contracts with overseas customers or suppliers or consultants that are denominated in foreign currency. As a result of these transactions there is exposure to fluctuations in foreign exchange rates. The principle currency risk faced by the business is the exchange rate between the Australian dollar and the US dollar. The Company holds cash denominated in US dollars and Australian dollars and may have material future expenditure in each of these currencies. Where possible, the Company matches foreign currency income and foreign currency expenditure as a natural hedge, holding foreign currency cash to facilitate this natural hedge. When foreign currency expenditure exceeds foreign currency revenue and foreign currency cash, the Company may consider purchasing foreign currency to meet anticipated requirements under spot and forward contracts.

Interest rate risk - The Company is exposed to changes in market interest rates as the Company holds cash and cash equivalents. The Company mitigates this risk through a series of term deposits structured to provide some certainty of financial returns.

Liquidity risk - The Company's financial liabilities, comprising trade and other payables and derivatives, are generally repayable within 1 – 3 months. The maturity and availability of financial assets, comprising cash and cash equivalents and trade and other receivables, are monitored and managed to ensure financial liabilities can be repaid when due.

Capital management - The Company monitors capital including share capital, retained earnings and reserves and the cash and cash equivalents presented in the consolidated statement of financial position. The Company has no debt. The key objective of the Company when managing its capital is to safeguard its ability to continue as a going concern, so that the Company can sustain the commercialisation and the future development of the research and development activities being performed by the Company.

DIRECTORS' INTERESTS IN THE SHARES, OPTIONS AND PERFORMANCE RIGHTS OF THE COMPANY

As at the date of this report, the interests of the Directors in ordinary shares, unlisted options and performance rights of the Company were:

	Shares		Options		Performance rights	
Director	**Directly**	**Indirectly**	**Directly**	**Indirectly**	**Directly**	**Indirectly**
Mr Vincent Ippolito	10,801,644	-	-	-	-	-
Mr Matthew Callahan	-	74,586,791	-	-	-	-
Dr William Bosch	18,836,702	-	-	-	-	-
Dr Stewart Washer	-	2,170,035	-	5,000,000	-	333,333
Mr Danny Sharp	2,131,313	-	4,000,000	-	333,333	-
Total	**31,769,659**	**76,756,826**	**4,000,000**	**5,000,000**	**333,333**	**333,333**

EVENTS SINCE THE END OF THE FINANCIAL YEAR

On 12 July 2024, the Group issued 23,000,000 performance rights and 16,000,000 options to employees. An additional 3,000,000 options are unissued but were granted during the 30 June 2024 period. All these instruments have been accounted for in these financial statements as they were determined to be granted for accounting purposes in the 30 June 2024 period. Refer to note 9 of this preliminary report for details to the terms, conditions and valuation of these instruments labelled as *Issuance #2* and *Issuance #3*.

Other than the matters above there are no matters or circumstances which have arisen since the end of the year which significantly affect or may significantly affect the operations of the Group, the results of those operations or the state of affairs of the Group in subsequent financial years.

ENVIRONMENTAL REGULATION

The Directors have considered compliance with the National Greenhouse and Energy Reporting Act 2007 which requires entities to report annual greenhouse gas emissions and energy use. For the year ended 30 June 2024, the Directors have assessed that there are no current reporting requirements but have committed to develop an ESG framework in the future.

LIKELY DEVELOPMENTS & EXPECTED RESULTS OF OPERATIONS

Other than as disclosed elsewhere in this report, there are no likely developments in the operations of the Company that were not finalised at the date of this report.

BOTANIX PHARMACEUTICALS LIMITED
ACN: 009 109 755

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the year ended 30 June 2024

	Note	2024 $	2023 $
Revenue from continuing operation			
Sales revenue		601,820	102,934
Total revenue from continuing operations	1	**601,820**	**102,934**
Other income			
Interest income		75,721	65,958
Research and development incentive scheme		1,467,667	3,669,439
Total other income	1	**1,543,388**	**3,735,397**
Employee expenses		(2,254,943)	(1,517,603)
Professional consulting expense	2	(4,324,880)	(2,868,546)
Research expenses		(1,812,938)	(5,727,498)
Depreciation of plant and equipment		(11,642)	(20,535)
Amortisation of right of use asset		-	(89,899)
Amortisation of intellectual property	5	(60,964)	-
Finance expenses		(10,659)	(81,736)
Other expenses	2	(1,363,767)	(1,153,803)
Foreign exchange gain/(loss)		57,208	(11,857)
Share based payments	9	(4,393,072)	(1,520,828)
Inventory provision expense	3	(1,839,260)	-
Total expenses		**(16,014,917)**	**(12,992,305)**
Loss before income tax expense		**(13,869,709)**	**(9,153,974)**
Income tax expense		-	-
Loss after income tax for the year		**(13,869,709)**	**(9,153,974)**
Other comprehensive income for the year:			
Items that may be reclassified subsequently to profit or loss:			
Foreign exchange translation difference		159,841	236,693
Other comprehensive income for the period, net of tax		**159,841**	**236,693**
Total comprehensive loss for the year attributed to members of Botanix Pharmaceuticals Limited		**(13,709,868)**	**(8,917,281)**
Loss per share for the year attributable to members of Botanix Pharmaceuticals Limited			
Basic loss per share (cents)	10	**(0.92)**	(0.79)
Diluted loss per share (cents)	10	**(0.92)**	(0.79)

The above Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the accompanying notes.

BOTANIX PHARMACEUTICALS LIMITED
ACN: 009 109 755

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 30 June 2024

	Note	2024 $	2023 $
ASSETS			
Current Assets			
Cash and cash equivalents		79,308,130	10,250,395
Inventory	3	1,209,374	3,147,031
Trade and other receivables	4	817,038	489,124
Research and development incentive scheme refundable	1	1,467,667	-
Prepayments		99,097	92,078
Total Current Assets		**82,901,307**	**13,978,628**
Non-current Assets			
Plant and equipment		71,777	65,376
Intangible assets	5	29,491,543	10,729,375
Other financial assets		-	62,644
Total Non-current Assets		**29,563,320**	**10,857,395**
Total Assets		**112,464,626**	**24,836,023**
LIABILITIES			
Current Liabilities			
Trade and other payables	6	3,624,623	1,733,296
Provisions		107,454	151,700
Total Current Liabilities		**3,732,077**	**1,884,996**
Total Liabilities		**3,732,077**	**1,884,996**
Net Assets		**108,732,549**	**22,951,027**
EQUITY			
Contributed equity	7	188,320,331	93,489,658
Reserves	8	10,702,140	6,041,423
Foreign currency translation reserve	8	501,719	341,878
Accumulated losses		(90,791,641)	(76,921,932)
Total Equity		**108,732,549**	**22,951,027**

The above Consolidated Statement of Financial Position should be read in conjunction with the accompanying notes.

BOTANIX PHARMACEUTICALS LIMITED
ACN: 009 109 755

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the year ended 30 June 2024

	Note	Contributed Equity	Accumulated Losses	Reserves	Foreign Currency Translation Reserve	Total
		$	$	$	$	$
Balance at 1 July 2023		93,489,658	(76,921,932)	6,041,423	341,878	22,951,027
Total comprehensive loss for the year						
Loss for the year		-	(13,869,709)	-	-	(13,869,709)
Total other comprehensive loss		-	-	-	159,841	159,841
Total comprehensive loss for the year		-	(13,869,709)	-	159,841	(13,709,868)
Transaction with equity holders:						
Ordinary shares issued net of costs	7	94,830,673	-	267,627	-	95,098,300
Share based payments	9	-	-	4,393,090	-	4,393,092
Balance at 30 June 2024		**188,320,331**	**(90,791,641)**	**10,702,140**	**501,719**	**108,732,549**

	Note	Contributed Equity	Accumulated Losses	Reserves	Foreign Currency Translation Reserve	Total
		$	$	$	$	$
Balance at 1 July 2022		71,475,764	(67,767,958)	4,338,786	105,185	8,151,777
Total comprehensive loss for the year						
Loss for the year		-	(9,153,974)	-	-	(9,153,974)
Total other comprehensive loss		-	-	-	236,693	236,693
Total comprehensive loss for the year		-	(9,153,974)	-	236,693	(8,917,281)
Transaction with equity holders:						
Ordinary shares issued net of costs	7	22,013,894	-	181,809	-	22,195,703
Share based payments	9	-	-	1,520,828	-	1,520,828
Balance at 30 June 2023		**93,489,658**	**(76,921,932)**	**6,041,423**	**341,878**	**22,951,027**

The above Consolidated Statement of Changes in Equity should be read in conjunction with the accompanying notes.

BOTANIX PHARMACEUTICALS LIMITED
ACN: 009 109 755

CONSOLIDATED STATEMENT OF CASH FLOWS

For the year ended 30 June 2024

	Note	2024	2023
		$	$
CASHFLOWS FROM OPERATING ACTIVITIES			
Interest received		75,721	65,215
Receipts from customers		1,063,536	518,398
R&D tax concession received		-	3,669,439
Payments to suppliers and employees		(9,266,538)	(16,247,096)
Finance costs		-	(80,020)
Net cash used in operating activities		**(8,127,282)**	**(12,074,064)**
CASHFLOWS FROM INVESTING ACTIVITIES			
Payment for property, plant and equipment		(112,700)	(7,572)
Payment for intangibles		(17,886,767)	(7,046,149)
Net cash used in investing activities		**(17,999,467)**	**(7,053,721)**
CASHFLOWS FROM FINANCING ACTIVITIES			
Repayment of lease liability		-	(122,414)
Proceeds from issue of shares		100,854,964	23,590,350
Transaction costs paid from the issue of shares		(5,756,644)	(1,438,359)
Repayment of borrowings		-	(1,849,236)
Proceeds from loan		-	1,849,237
Net cash provided / (used in) by financing activities		**95,098,320**	**22,029,578**
Net increase/(decrease) in cash held		68,971,572	2,901,793
Cash and cash equivalents at beginning of financial year		10,250,395	7,285,653
Foreign exchange adjustment		86,163	62,949
Cash and cash equivalents at end of financial year		**79,308,130**	**10,250,395**

The above Consolidated Statement of Cash Flows should be read in conjunction with the accompanying notes.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1: SALES REVENUE AND OTHER INCOME

	2024 $	2023 $
Royalty fees received	1,034,558	914,973
Royalty fees paid	(432,738)	(812,039)
Sales revenue	**601,820**	**102,934**
Interest income	75,721	65,958
Research and development incentive scheme	1,467,667	3,669,439
Total revenue and other income	**2,145,208**	**3,838,331**

NOTE 2: OTHER EXPENSES

Loss before Income Tax includes the following specific expenses:

	2024 $	2023 $
Corporate and commercial consultants	2,595,496	1,438,352
Corporate investor advisory	115,093	152,769
Legal fees	1,114,358	859,547
Other professional fees	499,933	417,878
Professional consulting expense	**4,324,880**	**2,868,546**
Insurance	295,827	222,717
Travel	341,947	306,983
Marketing and promotion	331,314	22,832
Milestone payment	-	445,648
Other operating costs	394,679	155,623
Other expenses	**1,363,767**	**1,153,803**

NOTE 3: INVENTORY

	2024 $	2023 $
Sofpironium Bromide	2,503,409	2,703,579
Packaging	514,333	443,452
Total gross inventory	**3,017,742**	**3,147,031**
Provision for obsolescence	(1,839,260)	-
Translation differences	30,892	-
Total inventory net of provision	**1,209,374**	**3,147,031**

NOTE 4: TRADE AND OTHER RECEIVABLES

	2024 $	2023 $
Trade receivables	455,696	397,318
Other receivables	361,342	91,806
Total trade and other receivables (net of GST)	**817,038**	**489,124**

NOTE 5: INTANGIBLE ASSETS

	2024 $	2023 $
At cost	29,552,507	10,729,375
Accumulated amortisation	(60,964)	-
	29,491,543	**10,729,375**

Sofpironium Bromide Licences	2024 $	2023 $
Opening balance	10,729,375	3,295,246
Additions	18,823,132	7,434,129
Amortisation expense	(60,964)	-
Closing balance	**29,491,543**	**10,729,375**

	Acquisition costs $	Development costs $	Total $
Balance at 1 July 2023	6,855,255	3,874,120	10,729,375
Additions [1]	12,927,813	749,636	13,677,449
Additions from internal development	-	5,145,683	5,145,683
Amortisation expense			(60,964)
Balance at 30 June 2024	**19,783,068**	**9,769,439**	**29,491,543**

	Acquisition costs $	Development costs $	Total $
Balance at 1 July 2022	3,295,246	-	3,295,246
Additions [2]	3,560,009	-	3,560,009
Additions from internal development	-	3,874,120	3,874,120
Balance at 30 June 2023	**6,855,255**	**3,874,120**	**10,729,375**

[1] The consolidated entity paid US$8.25m to Fresh Tracks Therapeutics Inc (previously known as Brickell Biotech) in July 2023 to extinguish the contracted future milestone and royalty payments due to Fresh Tracks under its Agreement. Legal fees of AUD$559K were also paid (and capitalised) during the period directly associated with this transaction. In addition, the consolidated entity incurred a US$500k charge from a contractor as a milestone payment that arose upon FDA approval granted for its Sofpironium Bromide product on 18 June 2024.

[2] As part of the acquisition of Sofpironium Bromide, the Company paid US$2m based on a positive "Day-74 letter" being received from the FDA after NDA filing being resolution of an uncertain event in the variable consideration as disclosed at 30 June 2022.

NOTE 6: TRADE AND OTHER PAYABLES

	2024 $	2023 $
Trade payables	2,728,365	1,390,702
Accrued bonuses	456,202	-
Sundry payables and other accrued expenses	440,056	342,594
	3,624,623	**1,733,296**

NOTE 7: CONTRIBUTED EQUITY

(a) Issued and Paid-Up Capital

	2024 Number	2024 $	2023 Number	2023 $
Fully paid ordinary shares	**1,810,037,788**	**188,320,331**	**1,312,460,376**	**93,489,658**

(b) Movements in fully paid shares on issue	Number	$
Balance as at 1 July 2023	1,312,460,376	93,489,658
Placement at $0.12	104,166,667	12,500,000
Placement at $0.13	103,846,154	13,500,000
Placement at $0.30	233,333,333	70,000,000
Exercise of options at $0.09	48,664,095	4,379,769
Exercise of options at $0.079	6,000,000	475,200
Cashless exercise of options by employee at $0.089[(1)]	1,567,163	79,360
Less: transaction costs [(2)]	-	(6,103,656)
Balance as at 30 June 2024	**1,810,037,788**	**188,320,331**

[(1)] During the period, an employee exercised 2,666,666 of options previously awarded as a share-based payment. These options were exercised using a cashless exercise method available to employees. The amount reported in dollars represents the fair value of the options previously recorded in the Group's share-based payment reserve and transferred to Contributed Equity under its accounting policies.

[(2)] As part of the placements completed during the period, the Company issued 8,000,000 options to the lead manager. The total value of these options recorded as transaction costs was $346,981. Refer to note 13 for further information on the valuation of these options.

NOTE 7: CONTRIBUTED EQUITY (CONTINUED)

(c) Issued Options

	Number
Unlisted Options	**46,533,333**

(d) Movements in options on issue	**2024 Number**	**2023 Number**
Balance as at 1 July	111,111,761	70,153,639
Add: options issued	10,450,000	76,530,464
Less: exercise of options	(57,480,773)	(32,572,342)
Less: forfeiture of options by employee	(2,083,334)	-
Less: expiry and cancellation of options(1)	(15,464,321)	(3,000,000)
Balance as at 30 June	**46,533,333**	**111,111,761**

(1) Included in the 30 June 2024 number is 666,667 of options that lapsed but were not yet cancelled by 30 June 2024

NOTE 8: RESERVES

	2024 $	**2023 $**
Share based payments reserve		
Balance at beginning of year	6,041,423	4,338,786
Share based payments expense	4,393,090	1,520,828
Exercise of options by employee under the ESIP	(79,354)	-
Issue of options (cost of raising capital)	346,981	181,809
Balance at end of year	**10,702,140**	**6,041,423**
Foreign currency translation reserve		
Balance at beginning of year	341,878	105,185
Effect for foreign currency translation during the year	159,841	236,693
Balance at end of year	**501,719**	**341,878**

NOTE 9: SHARE BASED PAYMENTS

Employee Securities Incentive Plan ("ESIP")

The ESIP was originally approved by shareholders on 14 June 2016 and re-approved on 19 November 2018 and 26 October 2021. In accordance with the provisions of the ESIP, Directors, employees and consultants may be granted options to purchase ordinary shares at an exercise price determined by the Board with regard to the market value of the shares when it resolves to offer the options. The options may only be granted to eligible participants after the Board considers the person's seniority, position, length of service, potential contribution and any other matters which the Board considers relevant.

Each share option converts into one ordinary share of the Company on exercise. No amounts are paid or payable to the Company by the recipient on receipt of the option. The options carry neither rights to dividends nor voting rights. Options may be exercised at any time from the date of vesting to the date of expiry. The number of options granted are determined by the Board.

Options on issue at 30 June 2024

Description	2024 Number	Weighted Average Exercise Price	2023 Number	Weighted Average Exercise Price
Options				
Opening balance	59,500,000	0.12	70,153,639	0.10
Issued during the period for remuneration [1]	2,450,000	0.105	5,000,000	0.102
Issued during the period to consultants	-	-	8,500,000	0.078
Issued during the period as transaction costs from the issue of shares	8,000,000	0.184	10,000,000	0.094
Exercised during the period	(8,666,666)	0.082	(31,153,639)	(0.051)
Forfeited during the period	(2,083,334)	0.095	-	-
Expired and cancelled during the period	(12,666,667)	0.242	(3,000,000)	(0.115)
Balance at 30 June	**46,533,333**	0.105	**59,500,000**	0.119

The weighted average exercise period is 0.95 years (2023: 1.39 years).

[1] The 5,000,000 options were granted and accounted for during the prior year, but issued during the current year.

Performance Rights on issue at 30 June 2024

Description	2024 Number	Weighted Average Exercise Price	2023 Number	Weighted Average Exercise Price
Performance Rights				
Opening balance	7,333,335	0.00	-	0.00
Issued during the period for remuneration	56,000,000	0.00	19,500,000	0.00
Lapsed during the period	(6,333,335)	0.00	-	0.00
Exercised during the period	-	0.00	(12,166,665)	0.00
Balance at 30 June	**57,000,000**	0.00	**7,333,335**	0.00

NOTE 9: SHARE BASED PAYMENTS (CONTINUED)

Total expenses arising from share-based payment transactions recognised during the year were as follows:

	2024 $	2023 $
Share options	1,320,590	542,362
Performance rights	3,072,502	978,466
Total Value of Share Based Payments expense	**4,393,092**	**1,520,828**

Options / performance rights granted in the year ended 30 June 2024

2.45 million Retention Options were issued under the Company's Employee Incentive Plan on 12 September 2023, expiring on 12 September 2026. The exercise price is $0.105 per option, valued at $0.1109 per option. The options vest subject to achievement of hurdles linked to ongoing employment, with the fair value vested over the resulting service periods. $174,219 has been recorded as an expense during the period for these options.

8 million Options were issued to Zenix Nominees following the share placements in July 2023 and December 2023. 6 million options were issued on 27 July 2023, expiring on 27 July 2025. The exercise price is $0.18 per option, and they are valued at $0.0377 per option. 2 million options were issued on 1 December 2023, expiring on 1 December 2025. The exercise price is $0.195 per option, and they are valued at $0.0564 per option. The extended value of these options of $346,981 was recorded as a reduction to Contributed Equity given the options represent a cost of issuing shares, as per note 11.

The Options were valued using Black Scholes with the below assumptions:

	Unlisted options Employee Share Scheme[1]	Unlisted options Broker Options	Unlisted options Broker Options
Number of options in series	2,450,000	6,000,000	2,000,000
Grant date share price	$0.18	$0.13	$0.165
Exercise price	$0.105	$0.18	$0.195
Expected volatility	67.83%	67.29%	72.41%
Option life	3 years	2 years	2 years
Dividend yield	0.00%	0.00%	0.00%
Interest rate	3.73%	3.92%	4.07%

[1] The fair value of the options has been vested from grant date to expected achievement date in relation to each performance hurdle.

56 million performance rights (PRs) were granted to Howard McKibbon on 24 August 2023 under the Company's ESIP. The performance rights have an expiry date of 31 August 2028 and a nil exercise price. The rights were valued by reference to the share price on grant date of $0.185. The following vesting conditions pertain to Mr McKibbon's performance rights:

NOTE 9: SHARE BASED PAYMENTS (CONTINUED)

Vesting Condition	Proportion of Rights that will vest
Tranche 1: The date that is 12 months following the FDA approval of Sofpironium Bromide, provided that: • the approved label for Sofpironium Bromide includes an efficacy and safety data set that supports promotion of the product in the US market; and • the CEO has had continuous employment with the Company up to and including that date.	9,333,334 Rights
Tranche 2: The date that is the later of 12 months after the later of the vesting date of Tranche 1, or 30 December 2025, provided that: • the Company has launched Sofpironium Bromide for commercial sale in the United States. • the Company has established a distribution network which is effectively providing reimbursed prescriptions to patients; and • the CEO has had continuous employment with the Company up to and including that date.	9,333,333 Rights
Tranche 3: 12 months after the vesting date of Tranche 2 provided that: • the Company has deployed its digital telehealth platform for the diagnosis of patients with hyperhydrosis; • the Company is generating revenue from prescriptions as a direct result from utilization of the telehealth platform; and • the CEO has had continuous employment with the Company up to and including that date.	9,333,333 Rights
Tranche 4: • Achieving US$45 million of revenue from the sales of Sofpironium Bromide in a financial year • the CEO has had continuous employment with the Company up to and including that date.	7,000,000 Rights
Tranche 5: • Achieving US$100 million of revenue from the sales of Sofpironium Bromide in a financial year. • the CEO has had continuous employment with the Company up to and including that date.	7,000,000 Rights
Tranche 6: • Achieving US$150 million of revenue from the sales of Sofpironium Bromide in a financial year. • the CEO has had continuous employment with the Company up to and including that date.	7,000,000 Rights

NOTE 9: SHARE BASED PAYMENTS (CONTINUED)

Tranche 7:

• Achieving US$250 million of revenue from the sale of products in a financial year. • the CEO has had continuous employment with the Company up to and including that date.	7,000,000 Rights

Management have assumed a more than likely probability of achievement of all above hurdles.

$2,902,862 has been recorded as an expense during the period for the issue of these performance rights. The fair value of the performance rights has been vested from grant date to expected achievement date in relation to each performance hurdle.

During the period, the Group also granted options and performance rights under its ESIP to employees and consultants as shown in the table on the following page. For options, the Group used a Black Scholes valuation model with the below assumptions. For performance rights, the fair value per instrument is the grant date share price. In all circumstances, under the ESIP, an employee or consultant must be continuously employed with or providing services to the Company on the date of vesting. As in-line with the accounting policy, the fair value of performance rights and options is expensed straight-line from grant date to the expected achievement date in relation to each performance hurdle.

NOTE 9: SHARE BASED PAYMENTS (CONTINUED)

Issuance #1

Type	**Options**	**Performance Rights**	**Performance Rights**	**Performance Rights**
Grant date	10 June 2024	10 May 2024	15 May 2024	13 May 2024
Exercise price	$0.24	$0.00	$0.00	$0.00
Grant date share price	$0.275	$0.275	$0.255	$0.28
Fair value at grant date	$0.168	$0.275	$0.255	$0.28
Expected volatility	75%	N/A	N/A	N/A
Life	4 years	4 years	5 years	4 years
Dividend yield	-	N/A	N/A	N/A
Interest rate	3.9%	N/A	N/A	N/A
Tranche	**Proportion of Rights that will vest**	**Proportion of Rights that will vest**	**Proportion of Rights that will vest**	**Proportion of Rights that will vest**
T1 – the date that is 12 months following FDA approval of Sofpironium Bromide, provided that: • The approved label for Sofpironium Bromide includes an efficacy and safety data set that supports promotion of the produce in the US market.	1,500,000	800,000	3,000,000	800,000
T2 – the date that is the later of 12-months after the vesting date of T1, or 30 December 2025, provided that: • The Company has launched Sofpironium Bromide for commercial sale in the United States; and • The Company has established a distribution network which is effectively providing reimbursed prescriptions to patients.	1,500,000	800,000	3,000,000	800,000
T3 – 12-months after the vesting date of Tranche 2 provided that: • The Company has deployed its digital telehealth platform for the diagnosis of patients with hyperhydrosis; and • The Company is generating revenue from prescriptions as a direct result from utilisation of the telehealth platform.	1,500,000	800,000	3,000,000	800,000
T4 – achieving US$45m of revenue from the sales of Sofpironium Bromide in a financial year.	1,500,000	400,000	1,500,000	400,000
T5 – achieving US100m of revenue from the sales of Sofpironium Bromide in a financial year.	1,500,000	400,000	1,500,000	400,000
T6 – achieving US$150m of revenue from the sales of Sofpironium Bromide in a financial year.	1,500,000	400,000	1,500,000	400,000
T7 – achieving US$250m of revenue from the sales of Sofpironium Bromide in a financial year.	1,000,000	400,000	1,500,000	400,000

NOTE 9: SHARE BASED PAYMENTS (CONTINUED)

Issuance #2

Type	**Options**	**Options**	**Options**
Grant date	20 June 2024	14 June 2024	13 June 2024
Exercise price	$0.364	$0.28	$0.28
Grant date share price	$0.335	$0.33	$0.31
Fair value at grant date	$0.165	$0.183	$0.167
Expected volatility	75%	75%	75%
Life	3 years	3 years	3 years
Dividend yield	-	-	-
Interest rate	3.9%	3.9%	3.9%
Tranche	**Proportion of Rights that will vest**	**Proportion of Rights that will vest**	**Proportion of Rights that will vest**
T1 – on FDA approval of Sofdra	1,000,000	2,000,000	1,000,000
T2 – 12-months from FDA approval of Sofdra	500,000	1,000,000	500,000
T3 – 24-months from FDA approval of Sofdra	500,000	1,000,000	500,000

$1,222,214 has been recorded as an expense during the period for the issue of these options (*Issuance #1* and *Issuance #2*). The fair value of the options has been vested from grant date to expected achievement date in relation to each performance hurdle.

NOTE 9: SHARE BASED PAYMENTS (CONTINUED)

Options / performance rights granted in the year ended 30 June 2023

8.5 million Options (valued at $0.0358 per option) were issued to Consultants on 14 March 2023, vesting 33.33% at 6, 12 and 24 months respectively from the issue date. Unvested options will expire if contractors cease to be engaged by the Group.

$158,746 has been recorded as an expense in the 2024 year for the issue of these options (2023: $111,016).

The Options were valued using Black Scholes with the below assumptions:

	Unlisted options
Number of options in series	8,500,000
Grant date share price	14 March 2023
Exercise price	$0.078
Expected volatility	65.0%
Option life	3 years
Dividend yield	0.0
Interest rate	3.22%

2.45 million Options (valued at $0.0408 per option) were granted to Employees on 8 June 2023, vesting 33.33% at 6, 12 and 24 months respectively from the issue date. Unvested options will expire if employees cease to be employed by the Group.

$32,136 has been recorded as an expense in the 2024 year for the issue of these options (2023: $26,307).

The Options were valued using Black Scholes with the below assumptions:

	Unlisted options
Number of options in series	2,450,000
Grant date share price	Note 1
Exercise price	$0.105
Expected volatility	65.0%
Option life	3 years
Dividend yield	0.0
Interest rate	3.22%

Note 1: the options have not been issued as at 30 June 2023 but were approved prior to 30 June 2023. They were issued on 12 September 2023.

NOTE 9: SHARE BASED PAYMENTS (CONTINUED)

10 million options vesting immediately, were issued to the lead manager for the placement completed in September 2022. The value of these options was capitalised as a cost of raising capital as per Note 14. The options expire on 12 September 2024. The exercise price and value of options are:

6m options with an exercise price of $0.08 per option valued at $0.021 per option.

2m options with an exercise price of $0.10 per option valued at $0.017 per option.

2m options with an exercise price of $0.13 per option valued at $0.012 per option.

The options were valued using Black Scholes with the below assumptions:

	Unlisted options	Unlisted options	Unlisted options
Number of options in series	6,000,000	2,000,000	2,000,000
Grant date share price	$0.066	$0.066	$0.066
Exercise price	$0.079	$0.099	$0.132
Expected volatility	65%	65%	65%
Option life	2 years	2 years	2 years
Dividend yield	0.00%	0.00%	0.00%
Interest rate	3.22%	3.22%	3.22%

13 million performance rights (valued at $0.063 per right) were granted to Directors on 21 November 2022 upon shareholder approval. One third of these rights vest on receipt of the Day 74 letter; one third on mid-cycle review (both vesting conditions satisfied) and one third on FDA approval. A $147,000 expense reversal was recorded in the 30 June 2024 period due to the lapse of the third tranche linked to the achievement of FDA approval prior to 31 December 2023 (2023: $693,000 expense recorded).

The performance rights were valued with reference to the share price on grant date ($0.063).

6 million performance rights (valued at $0.057 per right) were granted to Key Management Personnel on 29 December 2022. One third of these rights vest on receipt of the Day 74 letter; one third on mid-cycle review (both vesting conditions satisfied) and one third on FDA approval. A $57,466 expense reversal was recorded in the 30 June 2024 period due to the lapse of the third tranche linked to the achievement of FDA approval prior to 31 December 2023 (2023: $285,466 expense recorded).

The performance rights were valued with reference to the share price on grant date ($0.057).

A further 0.5 million performance rights were granted to other employees on consistent terms and conditions.

NOTE 10: LOSS PER SHARE

	2024 $	2023 $
Continuing operations		
Basic loss per share – cents	(0.92)	(0.79)
Diluted loss per share – cents	(0.92)	(0.79)
Loss used in the calculation of basic and diluted loss per share	(13,869,709)	(9,153,974)

	2024 No	2023 No
Weighted average number of ordinary shares outstanding during the year used in calculation of basic loss per share	1,501,563,514	1,153,951,540
Weighted average number of ordinary shares outstanding during the year used in calculation of diluted loss per share	1,501,563,514	1,153,951,540

Options outstanding during the year have not been taken into account in the calculation of the weighted average number of ordinary shares as they are not considered dilutive.